EFM
ACAD icon

E Fund Management’s Acadia Pharmaceuticals ACAD Stock Holding History

E Fund Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Sell
15,546
-7,291
-32% -$160K 0.01% 329
2026
Q1 		$508K Buy
+22,837
New +$546K 0.02% 292
2025
Q2 		$303K Sell
14,035
-4,683
-25% -$87K 0.01% 300
2025
Q1 		$311K Buy
18,718
+8,090
+76% +$147K 0.01% 304
2024
Q4 		$195K Sell
10,628
-7,704
-42% -$124K 0.01% 368
2024
Q3 		$282K Sell
18,332
-196
-1% -$3.27K 0.01% 269
2024
Q2 		$301K Buy
18,528
+40
+0.2% +$646 0.02% 231
2024
Q1 		$342K Sell
18,488
-4,405
-19% -$109K 0.02% 257
2023
Q4 		$717K Buy
22,893
+5,605
+32% +$134K 0.05% 110
2023
Q3 		$360K Sell
17,288
-780
-4% -$21.2K 0.03% 183
2023
Q2 		$433K Sell
18,068
-799
-4% -$17.8K 0.03% 144
2023
Q1 		$355K Sell
18,867
-10,303
-35% -$196K 0.03% 202
2022
Q4 		$464K Buy
29,170
+1,763
+6% +$27.6K 0.04% 142
2022
Q3 		$448K Buy
27,407
+1,786
+7% +$28.9K 0.04% 145
2022
Q2 		$361K Buy
25,621
+14,048
+121% +$262K 0.03% 205
2022
Q1 		$280K Buy
+11,573
New +$280K 0.01% 221
2021
Q4 		– Sell
-10,673
Closed -$177K – 302
2021
Q3 		$177K Buy
+10,673
New +$206K 0.01% 237

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

E Fund Management's ACAD Position: Q2 2026 in Review

E Fund Management reduced its Acadia Pharmaceuticals (ACAD) stake by 32% in Q2 2026, selling an estimated $160K and leaving 15,546 shares worth $393K. The position accounts for 0.01% of the portfolio, ranked #329.

E Fund Management first reported a position in ACAD in Q3 2021 and has held it in 17 quarters since. The position peaked at $717K in Q4 2023. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • E Fund Management held 15,546 shares of Acadia Pharmaceuticals worth $393K as of Q2 2026.
  • E Fund Management sold 7,291 Acadia Pharmaceuticals shares in Q2 2026, an estimated $160K.
  • Acadia Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q2 2026, its #329 holding.
  • E Fund Management first reported a position in Acadia Pharmaceuticals in Q3 2021 and has held it in 17 quarters since.
  • E Fund Management's Acadia Pharmaceuticals position peaked at $717K in Q4 2023.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.